

mRNA-1273 but not BNT162b2 induces antibodies against polyethylene glycol (PEG) contained in mRNA-based vaccine formulations

Juan Manuel Carreño^{1,7&*}, Gagandeep Singh^{1,7*}, Johnstone Tcheou^{1,7}, Komal Srivastava^{1,7}, Charles Gleason^{1,7}, Hiromi Muramatsu², Parnavi Desai^{1,7}, Judith A. Aberg³, Rachel L. Miller⁴, PARIS study group^{1,7}, Norbert Pardi², Viviana Simon^{1,3,5,6,7&}, Florian Krammer^{1,6,7&}

PARIS study group: Angela A. Amoako, Dalles Andre, Katherine F. Beach, Maria C. Bermúdez-González, Gianna Y. Cai, Christian Cognigni, Daniel L. Floda, Giulio Kleiner, Neko Lyttle, Wann A Mendez, Lubbertus CF Mulder, Annika Oostenink, Aria Rooker, Ashley Beathrese T. Salimbangon, Miti Saksena, Levy A. Sominsky

Affiliations

¹*Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA*

²*Department of Microbiology, University of Pennsylvania, Philadelphia, PA 19104, USA*

³*Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Icahn School of Medicine at Mount Sinai, New York, NY, USA*

⁴*Division of Clinical Immunology, Department of Medicine, Icahn School of Medicine at Icahn School of Medicine at Mount Sinai, New York, NY, USA*

⁵*The Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA*

⁶*Department of Pathology, Molecular and Cell Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA*

⁷*Center for Vaccine Research and Pandemic Preparedness (C-VARPP), Icahn School of Medicine at Mount Sinai, New York, NY, USA*

**Contributed equally*

&To whom correspondance should be addressed: Florian Krammer (florian.krammer@mssm.edu), Viviana Simon (viviana.simon@mssm.edu) and Juan Manuel Carreño (jm.carreno@mssm.edu)

31 **Abstract**

32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63

Two messenger RNA (mRNA)-based vaccines are widely used globally to prevent coronavirus disease 2019 (COVID-19). Both vaccine formulations contain PEGylated lipids in their composition, in the form of polyethylene glycol [PEG] 2000 dimyristoyl glycerol for mRNA-1273, and 2 [(polyethylene glycol)-2000]-N,N-ditetradecylacetamide for BNT162b2. It is known that some PEGylated drugs and products for human use that contain PEG, are capable of eliciting immune responses, leading to detectable PEG-specific antibodies in serum. In this study, we determined if any of the components of mRNA-1273 or BNT162b2 formulations elicited PEG-specific antibody responses in serum by enzyme linked immunosorbent assay (ELISA). We detected an increase in the reactivity to mRNA vaccine formulations in mRNA-1273 but not BNT162b2 vaccinees' sera in a prime-boost dependent manner. Furthermore, we observed the same pattern of reactivity against irrelevant lipid nanoparticles from an influenza virus mRNA formulation and found that the reactivity of such antibodies correlated well with antibody levels against high and low molecular weight PEG. Using sera from participants selected based on the vaccine-associated side effects experienced after vaccination, including delayed onset, injection site or severe allergic reactions, we found no obvious association between PEG antibodies and adverse reactions. Overall, our data shows a differential induction of anti-PEG antibodies by mRNA-1273 and BNT162b2. The clinical relevance of PEG reactive antibodies induced by administration of the mRNA-1273 vaccine, and the potential interaction of these antibodies with other PEGylated drugs remains to be explored.

64 Introduction

65
66 Since their introduction, vaccines currently used to prevent coronavirus disease 2019 (COVID-19)
67 have been extensively scrutinized with regard to their safety profile. Some individuals developed
68 adverse reactions following the vaccine administration, such as pain, itching, redness, swelling,
69 and induration at the injection site, or general adverse reactions including cough, diarrhea,
70 fatigue, fever, and headache (1, 2). These side effects are unpleasant but generally are not
71 clinically serious. More severe but very rare side effects, including myocarditis and pericarditis
72 (40 cases per million vaccinated male 12-29 year old vaccinees) have been described (3-5) and
73 anaphylaxis (0.001 - 0.0001 % of the vaccinated population) also has been reported (2).
74 Importantly, higher self-reported reactogenicity following administration of mRNA-1273 (from
75 Moderna) versus BNT162b2 (from Pfizer) has been described (6). Delayed large local reactions,
76 which are harmless but can be concerning for vaccinees, have been reported specifically to occur
77 in mostly female vaccinees who received mRNA-1273 (7, 8). However, so far, the cause of these
78 differences between the two mRNA-based vaccine formulations remains unclear.

79
80 It is known that some of the excipients contained in different drugs for human use can cause local
81 or systemic reactions, resulting in the induction of immune responses towards some of these
82 components (9). Furthermore, it has been suggested that certain components of the mRNA
83 vaccine formulations might be involved in the development of some of the adverse reactions
84 observed, including anaphylaxis (2, 9). Pertaining to the structure and composition of the two
85 mRNA-based vaccine formulations, both vaccines consist of nucleoside-modified mRNA which
86 encodes a diproline (2P)-stabilized, full-length, membrane-bound spike protein (3). Likewise,
87 both formulations contain charged and non-charged ionizable lipids, which form the core of the
88 lipid nanoparticles (LNPs), while 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), cholesterol
89 and a PEGylated lipids, give shape and stabilize the surface lipid bilayer (3) (**Table 1**). Particularly,
90 polyethylene glycol (PEG) contained in mRNA-based formulations may be linked to some cases
91 of anaphylaxis (10, 11). Indeed, the US Advisory Committee on Immunization Practices (ACIP)
92 recommended in the past the exclusion of people with known severe allergic reactions against
93 PEG and related compounds from receiving vaccine formulations containing these components

94 (12). Both, PEG and polysorbate 80, a component of the adenovirus vectored vaccine AZD1222,
95 as well as other compounds of similar nature, have been implicated in rare cases of
96 hypersensitivity reactions (9, 10, 13), and PEG is known to elicit antigen-specific antibody
97 responses in some individuals (10, 13-15).

98
99 Given that both of the current mRNA-based vaccine formulations - mRNA-1273 and BNT162b2 -
100 contain PEG in their composition, but vaccinated individuals display differential reactogenicity,
101 we evaluated whether serum antibodies from mRNA-based vaccine recipients were able to react
102 with homologous/heterologous mRNA vaccine formulations. Furthermore, we assessed if
103 differential patterns of reactivity of antibodies elicited by mRNA-1273 or BNT162b2 were
104 observed, and assessed the target components within the vaccine formulation.

105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122

123 **Materials and methods**

124

125 **Study participants and human samples**

126

127 Samples were collected as part of our ongoing institutional review board–approved, longitudinal
128 observational studies (Study ID-20-00442: 64 participants; Study ID-16-01215: one participant).
129 The majority of samples were selected from the PARIS (Protection Associated with Rapid
130 Immunity to SARS-CoV-2) study, which follows healthcare workers (HCWs) of the Mount Sinai
131 Health System. All participants signed informed consents prior to data and sample collection.
132 Information on SARS-CoV-2 mRNA vaccine-associated side-effects were collected using a survey
133 sent to the participants after the first and second vaccine dose. Samples were coded and analyzed
134 in a blinded manner.

135 Sixty longitudinal samples from 20 PARIS participants (10 BNT162b2 vaccinees and 10 mRNA-
136 1273 vaccinees) were selected at baseline, 18.9 days (arithmetic mean ± 2.4 SD) after the first
137 SARS-CoV-2 mRNA vaccine dose (prime) and 19.3 days (arithmetic mean ± 3.9 SD) after the
138 second SARS-CoV-2 mRNA vaccine dose (boost).

139 In addition, we selected longitudinal serum samples collected from participants who reported
140 experiencing more pronounced, unusual or delayed onset vaccine-associated side effects (7 days
141 arithmetic mean ± 5.2 SD) after the first mRNA vaccine dose. The sera were collected at baseline
142 (n=28 for BNT162b2 and n=19 for mRNA-1273 groups), 14.5 days (arithmetic mean ± 4.8 SD) after
143 the prime (n=23 for BNT162b2 and n=17 for mRNA-1273 groups) and 25.2 days (arithmetic mean
144 ± 11.6 SD) after the boost (n=26 for BNT162b2 and n=17 for mRNA-1273 groups).

145 The SARS-CoV-2 mRNA vaccine side effects reported from the participants selected based on
146 their vaccine associated side effects were generally mild to moderate and self-limiting (e.g.,
147 injection site pain/swelling, fever, fatigue, etc.) with a subset of participants (N: 8, all females,
148 three received BNT162b2 and five received mRNA-1273) reporting delayed onset, injection site
149 rashes, redness or swelling. Of note, all five participants receive a second vaccine dose and the
150 delayed onset skin reactions did not re-occur. Sera from a female participant who developed a
151 severe allergic reaction after the first BNT162b2 vaccine dose requiring hospitalization were also
152 included. This participant did not receive a second vaccine dose.

153 **Irrelevant mRNA-LNP production**

154 The mRNA used as an irrelevant control was designed based on the influenza virus
155 B/Colorado/06/2017 neuraminidase (NA) sequence. Production of the mRNA was performed as
156 described earlier (16, 17). Briefly, the codon-optimized NA gene was synthesized (Genscript) and
157 cloned into an mRNA production plasmid. A T7-driven *in vitro* transcription reaction (Megascript,
158 Ambion) using linearized plasmid template was performed to generate mRNA with 101
159 nucleotide long poly(A) tail. Capping of the mRNA was performed in concert with transcription
160 through addition of a trinucleotide cap1 analogue, CleanCap (TriLink) and m1 Ψ -5'-triphosphate
161 (TriLink) was incorporated into the reaction instead of UTP. Cellulose-based purification of NA
162 mRNA was performed as described (18). The mRNA was then tested on an agarose gel before
163 storing at -20°C.

164 The cellulose-purified m1 Ψ -containing NA mRNA was encapsulated in LNPs using a
165 self-assembly process as previously described wherein an ethanolic lipid mixture of ionizable
166 cationic lipid, phosphatidylcholine, cholesterol and polyethylene glycol-lipid was rapidly mixed
167 with an aqueous solution containing mRNA at acidic pH (19). The RNA-loaded particles were
168 characterized and subsequently stored at -80°C at a concentration of 1 mg/ml.

169

170 **Expression and purification of recombinant SARS-CoV-2 spike protein.** Recombinant SARS-CoV-
171 2 spike protein was produced using a mammalian cell protein expression system. Briefly, the
172 spike (S) gene sequence (GenBank: MN908947) was cloned into a mammalian expression vector
173 pCAGGs, as described (20, 21). Protein was expressed using the Expi293 Expression System
174 (Thermo Fisher Scientific), according to the manufacturer's instructions. Cell culture supernatant
175 was collected and clarified by centrifugation at 4000 x g, filtered, and purified with Ni-
176 nitrilotriacetic acid (NTA) agarose (QIAGEN). The purified protein was concentrated using Amicon
177 Ultracell (Merck Millipore) centrifugation units, and the buffer was exchanged to a phosphate
178 buffer solution (PBS, pH 7.4). Proteins were stored at -80°C until use.

179

180 **Enzyme linked immunosorbent assay (ELISA).** Antibody titers in vaccinees' sera were
181 determined against the recombinant trimeric spike protein of wild type SARS-CoV-2 as previously
182 described (21, 22). Spike and BSA ELISAs were performed using phosphate-buffered saline (PBS)

183 with 0.1% Tween-20 (PBS-T; Fisher Scientific) in washing, blocking, and diluting solutions. mRNA
184 vaccines BNT162b2 (from Pfizer) and mRNA-1273 (from Moderna), irrelevant mRNA LNPs, multi-
185 PEGylated bovine serum albumin (mPEG-BSA, 20 kDa, Life Diagnostics, Inc), and low molecular
186 weight PEG (3.35kDa, Sigma) based ELISAs were performed using a modified protocol in which
187 Tween-20 was excluded from washing/Ab solutions. Briefly, polystyrene 96-well microtiter plates
188 (Thermo Fisher Scientific) were coated overnight with mPEG-BSA (2 μ g/ml), BNT162b2 or mRNA-
189 1273 vaccine formulations (25 μ l/10ml), irrelevant mRNA lipid nanoparticles (0.5 μ g/ml) or BSA
190 (1% solution, MP Biomedicals). For IgE and BSA controls (shown in Supplementary Figure 2), ELISA
191 plates were coated with 2 μ g/ml of an IgE isotype control (Invitrogen) and BSA (1% solution, MP
192 Biomedicals) respectively. The following day, wells were washed and blocked with 200 μ l of 3%
193 non-fat milk (AmericanBio) in PBS for 1 h at room temperature (RT). After 1 h incubation, blocking
194 solution was removed and pre-diluted sera (in PBS 1% non-fat milk) were added at an initial
195 dilution of 1:50 followed by 2-fold serial dilutions. After 2 h incubation, plates were washed three
196 times with PBS and then incubated for 1 hour with anti-human IgG (Fab-specific) horse radish
197 peroxidase (HRP) secondary antibody produced in goat (Sigma-Aldrich), or IgM-HRP (Southern
198 Biotech) at a 1:3000 in 1% milk PBS. Specific spike/PEG-IgE antibodies were assessed by
199 incubating with an anti-IgE HRP conjugated antibody (Invitrogen) for 1 h at a 1:2000 dilution. For
200 the IgE control, plates were incubated with serial dilutions (2-fold) of the anti-IgE HRP conjugated
201 antibody (Invitrogen) starting at a 1:1000 dilution for 1 h. For the BSA control, plates were
202 incubated with serial dilutions (2-fold) of an anti-albumin (bovine serum) rabbit IgG fraction (anti-
203 BSA, Invitrogen) starting at a 1:1000 dilution for 1 h, followed by three washes with PBS and
204 addition of a donkey anti-rabbit IgG HRP conjugated antibody (CiteAb) at a 1:1000 dilution. Plates
205 were washed three times with PBS and 100 μ l/well of *O*-phenylenediamine dihydrochloride (OPD)
206 substrate (SigmaFast OPD; Sigma-Aldrich) were added. After 10 min incubation at RT, the
207 reaction was stopped by addition of 50 μ l of 3 M HCl solution. The optical density (OD) was
208 measured at 490 nm using a Synergy 4 plate reader (BioTek). Data were captured in excel and
209 are area under the curve (AUC) values were determined using Prism 9 (GraphPad Software, San
210 Diego, CA, USA).

211 **Statistical analyses.** Data plotting and statistical analyses were performed using GraphPad Prism
212 9 (GraphPad Software, San Diego, CA, USA). Statistically significant differences between post-
213 prime/post-boost vs baseline antibody levels were measured using a one-way ANOVA with
214 Tukey's multiple comparisons test. All adjusted P values of <0.05 were considered statistically
215 significant with a confidence interval of 95%.

216

217 **Results**

218 **mRNA-1273 vaccination induces antibodies against mRNA vaccine formulations in a prime-**
219 **boost dependent manner.** It has been hypothesized that the adverse reactions observed in some
220 individuals after administration of the currently available mRNA vaccines might be caused by
221 some of the formulation components (2, 11). To explore if vaccinees elicited antibodies against
222 components of the vaccine formulation, we used samples from individuals who received either
223 the mRNA-1273 or BNT162b2 mRNA vaccines. Samples were collected at baseline (n=10/group),
224 18.9 days (arithmetic mean \pm 2.4 SD) after the prime (n=10/group) or 19.3 days (arithmetic mean
225 \pm 3.9 SD) after the boost (n=10/group). Initially, to confirm the induction of antibodies after the
226 vaccine administration, we measured the IgG titers against a recombinant version of the spike
227 protein via ELISA. We detected a prime-boost dependent induction of anti-spike antibodies after
228 vaccination, with levels oscillating around 10^3 area under the curve (AUC) units after prime with
229 mRNA-1273 or BNT162b2, and 10^4 after the boost administration (Figs. **1A** and **1B**). Then, we
230 coated ELISA plates with a standard amount of each of the vaccine formulations resuspended in
231 PBS and assessed binding of IgG antibodies. We found that sera collected after vaccination with
232 mRNA-1273 had increasing reactivity against both the BNT162b2 (Fig. **1C**) and mRNA-1273 (Fig.
233 **1D**) formulations, and that the increased reactivity was vaccination-dependent, with a moderate
234 increase after the prime administration and higher levels induced after the boost. Interestingly,
235 this increase in reactivity was not evident in sera from individuals receiving the BNT162b2
236 vaccine, either against the BNT162b2 or mRNA-1273 formulations (Figs. **1E** and **1F**). Overall, these
237 data suggest that mRNA-1273 but not BNT162b2 vaccination induces antibodies against some
238 component(s) of the vaccine formulations.

239 **Antibodies reactive towards the vaccine formulation are directed against the lipid**
240 **nanoparticles and react with polyethylene glycol (PEG).** Lipid nanoparticles contained in the
241 currently used mRNA vaccine formulations, as well as other drugs and other cosmetic and health
242 products for human use, contain PEG and have the potential to elicit immune responses against
243 it (10, 13-15). To dissect the target within the vaccine formulation to which mRNA-1273-induced
244 antibodies bind, we coated ELISA plates with LNPs carrying a SARS-CoV-2 unrelated, irrelevant
245 mRNA (encoding influenza virus neuraminidase). Similar to the reactivity overserved against the
246 BNT162b2 and mRNA-1273 formulations, we detected an increase in the reactivity against the
247 irrelevant mRNA-LNPs in individuals receiving the mRNA-1273 vaccine (Fig. **2B**), but not in those
248 ones vaccinated with BNT162b2 (Fig. **2A**), suggesting the reactivity is independent of the
249 sequence of the mRNA contained in the formulation.

250
251 Next, we assessed whether vaccination induced antibodies reacted to PEG. We measured the
252 binding of sera from mRNA-1273 and BNT162b2 vaccinated individuals to a PEGylated form of
253 BSA (PEG-BSA) containing high molecular weight PEG (20kDa). Again, we found that individuals
254 vaccinated with mRNA-1273, had an increase in antibodies against PEG-BSA in a vaccination-
255 dependent manner (Fig. **2D**), whereas no significant increase of antibody titers in individuals
256 receiving the BNT162b2 vaccine was observed (Fig. **2C**). As an alternative experimental approach,
257 we coated high binding polystyrene plates directly with a low molecular weight PEG (3.35 kDa)
258 molecule and performed similar ELISAs. Although this method seemed to be less sensitive than
259 the PEG-BSA ELISA, similarly we observed that individuals vaccinated with mRNA-1273, had
260 increased reactivity to PEG, particularly after the boost (Fig. **2E**), but there was no increase in
261 antibody titers following BNT162b2 administration (Fig. **2F**). Overall, these results suggest that
262 the antibodies induced towards the vaccine formulation components may be directed against
263 PEG, which is present in the vaccine formulation.

264
265 **PEG as the target of mRNA-1273-induced antibodies.** To assess in a systematic manner if the
266 formulation-reactive antibodies induced in mRNA-1273 vaccine recipients were directed against
267 PEG, we performed correlation analyses using the AUC values obtained in the different ELISAs

268 performed. We found that the mRNA-1273 induced antibodies detected against the BNT162b2
269 (Fig. **3A**) or mRNA-1273 (Fig. **3B**) vaccine formulations not only correlated well with PEG as
270 measured by using PEGylated BSA, but a correlation was observed between the PEGylated-BSA
271 AUC values and the irrelevant mRNA-LNPs (Fig. **3C**), as well as with the low molecular weight PEG
272 (3.35kDa) AUCs (Fig. **3D**). Moreover, the independent correlation of PEGylated-BSA AUC values
273 vs the BNT162b2 or mRNA-1273 formulation, the irrelevant mRNA-LNPs, or the low molecular
274 weight PEG AUCs, increased in a prime-boost dependent manner, with the lowest correlation
275 observed at baseline, and increasing correlations after the prime, followed by high correlations
276 after the boost (Supplementary Fig. **1**). The absolute values of the geometric mean AUCs for every
277 ELISA and the fold induction after the prime or the boost are shown in **Table 2**. Overall, these
278 analyses support that the antibodies detected in mRNA-1273 vaccine recipients, which react
279 towards the BNT162b2 or mRNA-1273 vaccine formulations, are directed towards the PEG
280 component of the formulations.

281
282 To explore if vaccinees displayed other classes of anti-PEG antibodies, we measured the reactivity
283 of IgM using the PEGylated BSA based ELISA. Similar to the IgG pattern previously observed, we
284 detected PEG-specific IgM - although at low levels - in the mRNA-1273 recipients in a vaccination
285 dependent manner (Fig. **4B**), however no induction of IgM in the BNT162b2 vaccinees (Fig. **4A**).
286 Moreover, we assessed whether individuals could potentially induce IgE antibodies directed to
287 PEG in response to vaccination, however levels of PEG-specific IgE were undetectable in all the
288 participants, irrespective of the vaccine type received (Figs. **4C** and **4D**). As a control for IgE
289 detection, we used plates coated with house dust mite (HDM) antigens, which allowed detecting
290 IgE in some of the participants (Supplementary Fig. **2**). Moreover, as a control to ensure that the
291 anti-PEG antibodies detected through this work were directed specifically against PEG, and
292 exclude the possibility that the BSA contained in the PEG-BSA reagent was as a target of the
293 reactivity detected, we performed ELISAs in plates pre-coated with 1% BSA (Figs. **4E** and **4F**). We
294 detected residual reactivity in three individuals, although at levels very close to the limit of
295 detection. These residual antibodies were, however, detected in both the BNT162b2 and mRNA-
296 1273 groups, and were irrespective of the vaccination time point. Overall, these results indicate

297 that mRNA-1273 administration leads to the induction of specific IgG and IgM, but not IgE
298 antibodies against PEG.

299

300 **Anti-PEG antibodies in a subgroup of participants with reported vaccine associated side effects**
301 **including delayed onset, injection site rash/erythema or severe allergic reaction.** A small
302 proportion of individuals have experienced delayed large local reactions after receiving the
303 mRNA-1273 vaccine (7, 8). To assess whether individuals who experienced delayed onset
304 reactions or other types of adverse reactions following vaccination, mounted differential anti-
305 PEG antibodies at baseline or after vaccination, we used samples from a selection of study
306 participants that reported vaccine-associated side effects such as delayed onset reactions
307 including injection site rashes (N=8) or severe allergic reaction (N=1). Overall, although levels of
308 anti-PEG antibodies were slightly higher at baseline, we did not find a significant association
309 between baseline anti-PEG titers and antibody induction after vaccination with mRNA-1273 or
310 BNT162b2. However, individuals receiving the mRNA-1273 formulation (Fig. **5B**), but not the ones
311 receiving the BNT162b2 vaccine (Fig. **5A**), induced significantly higher levels of anti-PEG
312 antibodies in a vaccination-dependent manner, similar to the findings described above. In
313 summary, these findings indicate that although there is an increase in the anti-PEG antibodies in
314 the mRNA-1273 vaccinees, there was no obvious association between PEG antibodies and
315 adverse reactions. Pre-existing anti-PEG levels are not associated with a more robust PEG
316 antibody induction following vaccination.

317
318
319
320
321
322
323
324
325
326
327
328
329
330

331 **Discussion**

332
333 Some of the current vaccines to prevent COVID-19 have unique properties as compared to any
334 other licensed vaccines in history. They are based on mRNA encapsulated in lipid nanoparticles
335 and they do not contain the target antigen which is coded by the mRNA and produced in the
336 vaccinee's cells. The LNPs contain lipidic components of diverse nature including PEGylated lipids.
337 Polyethylene glycol (PEG) is found in different drugs, cosmetics and health products for human
338 use (10, 23). Administration of animals with PEGylated proteins of different nature can induce
339 PEG-specific antibodies (24). Likewise, humans are able to induce anti-PEG antibodies following
340 administration of certain PEGylated drugs (14, 25-27). Moreover, pre-existing anti-PEG
341 antibodies are present in some individuals and can interfere with activities of PEGylated drugs
342 (15, 28).

343
344 Here, we found that a proportion of study participants receiving SARS-CoV-2 mRNA vaccines
345 mount anti-PEG antibodies to variable levels. Not every study participant receiving the mRNA-
346 1273 vaccine displayed high levels of anti-PEG antibodies post-vaccination, and not every
347 individual experiencing delayed onset side effects such as injection site reactions post-
348 vaccination had pre-existing anti-PEG levels. This suggests that although PEG contained in the
349 mRNA-1273 vaccine formulation is recognized by the immune system and antibodies are induced
350 against this molecule in some of the vaccinees, such high levels of antibodies – either at baseline
351 or induced by vaccination – do not directly correlate with the emergence of delayed large local
352 reactions. Although we cannot establish an association between the levels of PEG-reactive
353 antibodies and the higher reactogenicity observed in mRNA-1273 vaccinees, our findings suggest
354 that perhaps anti-formulation immune responses are contributing to the higher reactogenicity
355 sometimes observed with mRNA-1273 compared to BNT162b2.

356
357 The pre-existing antibody levels against PEG could be due to previous exposures to PEGylated
358 drugs (14, 25-27) or PEG-containing products (23). Importantly, we assessed the presence of
359 spike- or PEG- specific IgE antibodies and we did not find detectable levels of IgE antibodies,
360 including in the one participant who experienced a severe allergic reaction in response to

361 vaccination. Our results are in line with previous findings detecting PEG-specific IgG following
362 vaccination, but a lack of IgE (29). Allergy skin testing to PEG also was negative (unpublished
363 data). Immediate allergic reactions following vaccination, such as anaphylaxis, are likely to be
364 mediated by IgE-independent mechanisms of diverse nature (29), and the relevance of PEG-
365 specific IgG induced by vaccination remains to be investigated. Interestingly, via a genome-wide
366 association study, an immunoglobulin heavy chain (IGH) locus has been associated with the anti-
367 PEG IgM response (30). Although such association was not present for IgG, IGH polymorphisms
368 associated with switched anti-PEG IgG subsets require further exploration.

369
370 Differential immunogenicity of PEG molecules containing a methoxy (mPEG), hydroxy (H)-PEG
371 or t-butoxy (t-BuO-PEG) distal terminal groups has been described, with mPEG being more prone
372 to induce specific responses against this terminal group (31). Notwithstanding, the majority PEG-
373 specific monoclonal antibodies (mAbs) recognize the backbone of the molecule, meaning the
374 repeated ethylene oxide subunits (28, 32-34). Although the currently used mRNA formulations
375 incorporate different forms of PEG, both the polyethylene glycol [PEG] 2000 dimyristoyl glycerol
376 contained in the mRNA-1273 formulation, and the 2 [(polyethylene glycol)-2000]-N,N-
377 ditetradecylacetamide contained in the BNT162b2 formulation, bear a methoxy terminal group.
378 Hence, it is unlikely that the differential patterns of anti-PEG antibodies detected in mRNA-1273
379 vs BNT162b2 vaccinee's sera, are due to PEG structural differences in the formulations, but
380 rather, this might be the result of the higher dose of mRNA given to mRNA-1273 vaccine
381 recipients - 100µg for mRNA-1273 vs 30µg for BNT162b2, the result of the higher PEGylated lipid
382 dose in mRNA-1273 or the way PEG is presented by the carrier lipid (35). Moreover, serum from
383 mRNA-1273 vaccine recipients was able to recognize components of both formulations in a
384 prime-boost dependent manner. It remains to be explored whether the anti-PEG antibodies
385 induced following vaccination are directed towards the backbone of the PEG molecule, or the
386 methoxy group present in PEG from both formulations. Overall, our study reports the induction
387 of PEG antibodies following administration of one of the currently used mRNA-based vaccine
388 formulation. The clinical relevance of PEG-reactive antibodies induced by mRNA-1273

389 administration and the potential interaction of these antibodies with other PEGylated drugs
390 remain to be explored.

391

392 **Acknowledgments**

393 We thank the study participants for their generosity and willingness to participate in longitudinal
394 COVID-19 research studies. None of this work would be possible without their contributions.

395 This work is part of the PARIS/SPARTA studies funded by the NIAID Collaborative Influenza
396 Vaccine Innovation Centers (CIVIC) contract 75N93019C00051. In addition, this work was also
397 partially funded by NIAID U19AI168631-01 and the Centers of Excellence for Influenza Research
398 and Surveillance (CEIRS, contract # HHSN272201400008C), the JPB Foundation, the Open
399 Philanthropy Project (research grant 2020-215611 (5384) and by anonymous donors. Finally, this
400 effort was also supported by the Serological Sciences Network (SeroNet) in part with Federal
401 funds from the National Cancer Institute, National Institutes of Health, under Contract No.
402 75N91019D00024, Task Order No. 75N91021F00001. The content of this publication does not
403 necessarily reflect the views or policies of the Department of Health and Human Services, nor
404 does mention of trade names, commercial products or organizations imply endorsement by the
405 U.S. Government. We thank Acuitas Therapeutics for LNP-encapsulating the NA mRNA used in
406 this study.

407

408 **Conflict of interest statement**

409 The Icahn School of Medicine at Mount Sinai has filed patent applications relating to SARS-CoV-
410 2 serological assays and NDV-based SARS-CoV-2 vaccines which list Florian Krammer as co-
411 inventor. Viviana Simon is also listed on the serological assay patent application as co-inventor.
412 Mount Sinai has spun out a company, Kantaro, to market serological tests for SARS-CoV-2. Florian
413 Krammer has consulted for Merck and Pfizer (before 2020), and is currently consulting for Pfizer,
414 Seqirus, 3rd Rock Ventures, Merck and Avimex. The Krammer laboratory is also collaborating with
415 Pfizer on animal models of SARS-CoV-2.

416

417

418 **Author contributions:**

419 F.K., V.S. and J.M.C. conceptualized study; CG, KS and the PARIS study group enrolled participants,
420 collected data, evaluated surveys and provided biospecimen and metadata, G.S., J.M.C, C.G.,
421 H.M., J.T., P.D. and the PARIS study group performed experiments; J.M.C., G.S., and J.T. analyzed
422 data; J.M.C., V.S., and F.K. administered the project; F.K., V.S., and N.P. provided resources; J.M.C.
423 wrote original draft. All authors reviewed, edited and approved the final version of the
424 manuscript, and have had access to the raw data.

425

426 **References**

427

- 428 1. Chen M, Yuan Y, Zhou Y, Deng Z, Zhao J, Feng F, et al. Safety of SARS-CoV-2 vaccines: a
429 systematic review and meta-analysis of randomized controlled trials. *Infect Dis Poverty*.
430 2021;10(1):94.
- 431 2. Castells MC, Phillips EJ. Maintaining Safety with SARS-CoV-2 Vaccines. *N Engl J Med*.
432 2021;384(7):643-9.
- 433 3. Buschmann MD, Carrasco MJ, Alishetty S, Paige M, Alameh MG, Weissman D.
434 Nanomaterial Delivery Systems for mRNA Vaccines. *Vaccines (Basel)*. 2021;9(1).
- 435 4. Wallace M, Moulia D, Blain AE, Ricketts EK, Minhaj FS, Link-Gelles R, et al. The Advisory
436 Committee on Immunization Practices' Recommendation for Use of Moderna COVID-19 Vaccine
437 in Adults Aged ≥ 18 Years and Considerations for Extended Intervals for Administration of
438 Primary Series Doses of mRNA COVID-19 Vaccines - United States, February 2022. *MMWR Morb*
439 *Mortal Wkly Rep*. 2022;71(11):416-21.
- 440 5. Oster ME, Shay DK, Su JR, Gee J, Creech CB, Broder KR, et al. Myocarditis Cases Reported
441 After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021. *JAMA*.
442 2022;327(4):331-40.
- 443 6. Chapin-Bardales J, Gee J, Myers T. Reactogenicity Following Receipt of mRNA-Based
444 COVID-19 Vaccines. *JAMA*. 2021;325(21):2201-2.
- 445 7. Blumenthal KG, Freeman EE, Saff RR, Robinson LB, Wolfson AR, Foreman RK, et al. Delayed
446 Large Local Reactions to mRNA-1273 Vaccine against SARS-CoV-2. *N Engl J Med*.
447 2021;384(13):1273-7.
- 448 8. Johnston MS, Galan A, Watsky KL, Little AJ. Delayed Localized Hypersensitivity Reactions
449 to the Moderna COVID-19 Vaccine: A Case Series. *JAMA Dermatol*. 2021;157(6):716-20.
- 450 9. Stone CA, Jr., Rukasin CRF, Beachkofsky TM, Phillips EJ. Immune-mediated adverse
451 reactions to vaccines. *Br J Clin Pharmacol*. 2019;85(12):2694-706.
- 452 10. Chen BM, Cheng TL, Roffler SR. Polyethylene Glycol Immunogenicity: Theoretical, Clinical,
453 and Practical Aspects of Anti-Polyethylene Glycol Antibodies. *ACS Nano*. 2021;15(9):14022-48.
- 454 11. Klimek L, Novak N, Cabanillas B, Jutel M, Bousquet J, Akdis CA. Allergenic components of
455 the mRNA-1273 vaccine for COVID-19: Possible involvement of polyethylene glycol and IgG-
456 mediated complement activation. *Allergy*. 2021;76(11):3307-13.

- 457 12. Dooling K, McClung N, Chamberland M, Marin M, Wallace M, Bell BP, et al. The Advisory
458 Committee on Immunization Practices' Interim Recommendation for Allocating Initial Supplies of
459 COVID-19 Vaccine - United States, 2020. *MMWR Morb Mortal Wkly Rep.* 2020;69(49):1857-9.
- 460 13. Caballero ML, Krantz MS, Quirce S, Phillips EJ, Stone CA, Jr. Hidden Dangers: Recognizing
461 Excipients as Potential Causes of Drug and Vaccine Hypersensitivity Reactions. *J Allergy Clin*
462 *Immunol Pract.* 2021;9(8):2968-82.
- 463 14. Hershfield MS, Ganson NJ, Kelly SJ, Scarlett EL, Jaggars DA, Sundry JS. Induced and pre-
464 existing anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for
465 refractory gout, including in organ transplant recipients. *Arthritis Res Ther.* 2014;16(2):R63.
- 466 15. Armstrong JK, Hempel G, Koling S, Chan LS, Fisher T, Meiselman HJ, et al. Antibody against
467 poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic
468 leukemia patients. *Cancer.* 2007;110(1):103-11.
- 469 16. Freyn AW, Ramos da Silva J, Rosado VC, Bliss CM, Pine M, Mui BL, et al. A Multi-Targeting,
470 Nucleoside-Modified mRNA Influenza Virus Vaccine Provides Broad Protection in Mice. *Mol Ther.*
471 2020;28(7):1569-84.
- 472 17. Freyn AW, Pine M, Rosado VC, Benz M, Muramatsu H, Beattie M, et al. Antigen
473 modifications improve nucleoside-modified mRNA-based influenza virus vaccines in mice. *Mol*
474 *Ther Methods Clin Dev.* 2021;22:84-95.
- 475 18. Baiersdorfer M, Boros G, Muramatsu H, Mahiny A, Vlatkovic I, Sahin U, et al. A Facile
476 Method for the Removal of dsRNA Contaminant from In Vitro-Transcribed mRNA. *Mol Ther*
477 *Nucleic Acids.* 2019;15:26-35.
- 478 19. Sternfeld M, Finkelstein Y, Hai E, Hod I. Tension headache treated by anti-inflammatory
479 drug injected into GB 20 acupuncture point. *Am J Chin Med.* 1986;14(3-4):171-4.
- 480 20. Amanat F, Stadlbauer D, Strohmeier S, Nguyen THO, Chromikova V, McMahon M, et al. A
481 serological assay to detect SARS-CoV-2 seroconversion in humans. *Nat Med.* 2020;26(7):1033-6.
- 482 21. Stadlbauer D, Tan J, Jiang K, Hernandez MM, Fabre S, Amanat F, et al. Repeated cross-
483 sectional sero-monitoring of SARS-CoV-2 in New York City. *Nature.* 2021;590(7844):146-50.
- 484 22. Carreno JM, Alshammary H, Singh G, Raskin A, Amanat F, Amoako A, et al. Evidence for
485 retained spike-binding and neutralizing activity against emerging SARS-CoV-2 variants in serum
486 of COVID-19 mRNA vaccine recipients. *EBioMedicine.* 2021;73:103626.
- 487 23. Frujtier-Polloth C. Safety assessment on polyethylene glycols (PEGs) and their derivatives
488 as used in cosmetic products. *Toxicology.* 2005;214(1-2):1-38.
- 489 24. Richter AW, Akerblom E. Antibodies against polyethylene glycol produced in animals by
490 immunization with monomethoxy polyethylene glycol modified proteins. *Int Arch Allergy Appl*
491 *Immunol.* 1983;70(2):124-31.
- 492 25. Ganson NJ, Kelly SJ, Scarlett E, Sundry JS, Hershfield MS. Control of hyperuricemia in
493 subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a
494 phase I trial of subcutaneous PEGylated urate oxidase. *Arthritis Res Ther.* 2006;8(1):R12.
- 495 26. Longo N, Harding CO, Burton BK, Grange DK, Vockley J, Wasserstein M, et al. Single-dose,
496 subcutaneous recombinant phenylalanine ammonia lyase conjugated with polyethylene glycol in
497 adult patients with phenylketonuria: an open-label, multicentre, phase 1 dose-escalation trial.
498 *Lancet.* 2014;384(9937):37-44.

499 27. Sundy JS, Ganson NJ, Kelly SJ, Scarlett EL, Rehrig CD, Huang W, et al. Pharmacokinetics
500 and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in
501 patients with refractory gout. *Arthritis Rheum.* 2007;56(3):1021-8.

502 28. Yang Q, Lai SK. Anti-PEG immunity: emergence, characteristics, and unaddressed
503 questions. *Wiley Interdiscip Rev Nanomed Nanobiotechnol.* 2015;7(5):655-77.

504 29. Warren CM, Snow TT, Lee AS, Shah MM, Heider A, Blomkalns A, et al. Assessment of
505 Allergic and Anaphylactic Reactions to mRNA COVID-19 Vaccines With Confirmatory Testing in a
506 US Regional Health System. *JAMA Netw Open.* 2021;4(9):e2125524.

507 30. Chang CJ, Chen CH, Chen BM, Su YC, Chen YT, Hershfield MS, et al. A genome-wide
508 association study identifies a novel susceptibility locus for the immunogenicity of polyethylene
509 glycol. *Nat Commun.* 2017;8(1):522.

510 31. Sherman MR, Williams LD, Sobczyk MA, Michaels SJ, Saifer MG. Role of the methoxy
511 group in immune responses to mPEG-protein conjugates. *Bioconjug Chem.* 2012;23(3):485-99.

512 32. Cheng TL, Cheng CM, Chen BM, Tsao DA, Chuang KH, Hsiao SW, et al. Monoclonal
513 antibody-based quantitation of poly(ethylene glycol)-derivatized proteins, liposomes, and
514 nanoparticles. *Bioconjug Chem.* 2005;16(5):1225-31.

515 33. Tsai NM, Cheng TL, Roffler SR. Sensitive measurement of polyethylene glycol-modified
516 proteins. *Biotechniques.* 2001;30(2):396-402.

517 34. Su YC, Chen BM, Chuang KH, Cheng TL, Roffler SR. Sensitive quantification of PEGylated
518 compounds by second-generation anti-poly(ethylene glycol) monoclonal antibodies. *Bioconjug*
519 *Chem.* 2010;21(7):1264-70.

520 35. Risma KA, Edwards KM, Hummell DS, Little FF, Norton AE, Stallings A, et al. Potential
521 mechanisms of anaphylaxis to COVID-19 mRNA vaccines. *J Allergy Clin Immunol.*
522 2021;147(6):2075-82 e2.

523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542

543 **Table 1.** Components of mRNA-1273 and BNT162b2 formulations.

	mRNA-1273	BNT162b2
Nucleic acid	messenger ribonucleic acid (mRNA)	messenger ribonucleic acid (mRNA)
Lipidic components	SM-102	ALC 315
	polyethylene glycol [PEG] 2000 dimyristoyl glycerol [DMG]	2 [(polyethylene glycol)-2000]-N,N-ditetradecylacetamide
	Cholesterol	Cholesterol
	1,2-distearoyl-sn-glycero-3-phosphocholine [DSPC]	1,2-Distearoyl-sn-glycero-3-phosphocholine [DSPC]
Other components	Tromethamine, tromethamine hydrochloride, acetic acid, sodium acetate trihydrate, and sucrose	Tromethamine, tromethamine hydrochloride, and sucrose or* potassium chloride, monobasic potassium phosphate, sodium chloride, dibasic sodium phosphate dihydrate, and sucrose

*BNT162b2 vaccine for individuals 12 years of age and older contain one of the two sets of additional ingredients

544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564

565 **Table 2.** Geometric means of AUC and AUC fold change for each ELISA antigen.

	Timepoint/ vaccine	Geometric mean AUCs		Geometric mean AUC fold change	
		BNT162b2 G.M. AUC	mRNA-1273 G.M. AUC	BNT162b2 (G.M.F.I)	mRNA-1273 (G.M.F.I)
Spike	Prime	1569.32	2043.64	313.86	408.73
	Boost	7405.92	7974.32	1481.18	1594.86
BNT162b2 LNP	Prime	0.54	1.54	0.92	2.25
	Boost	0.58	7.04	1.07	4.28
mRNA-1273 LNP	Prime	0.55	1.84	1.1	2.6
	Boost	0.66	8.62	1.32	12.2
Nonspecific LNP	Prime	8.98	27.44	1.1	3.54
	Boost	9.6	49.39	1.07	2.12
PEGylated BSA	Prime	10.01	49.64	1.26	5.06
	Boost	8.87	169.14	1.11	17.25
Low molecular weight PEG	Prime	0.5	0.89	1	1.78
	Boost	0.61	1.78	1.22	9.29
BSA	Prime	5.43	5.38	0.92	0.96
	Boost	5.78	8.06	0.98	1.44

566
 567 Geometric mean (G.M.) of all the area under the curve (AUC) values measured after the prime or the
 568 boost are shown in the left panels. Geometric mean of fold induction (G.M.F.I) values, expressed as the
 569 ratio between prime or boost AUCs and the baseline AUC for each of the participants is shown in the right
 570 panels. Prime: First SARS-CoV-2 vaccine dose; Boost: Second SARS-CoV-2 vaccine dose

571
 572
 573
 574
 575
 576
 577
 578
 579
 580
 581
 582
 583
 584
 585
 586
 587
 588

589 **Figure Legends**

590

591 **Figure 1. Antibodies against SARS-CoV-2 spike and mRNA-based vaccine formulations in**
592 **vaccinees' sera.** Sera from BNT162b2 (left column) or mRNA-1273 (right column) vaccinees
593 collected at baseline (n=10 for BNT162b2 and n=10 for mRNA-1273 groups), 18.9 days (arithmetic
594 mean \pm 2.4 SD) after the prime (n=10 for BNT162b2 and n=10 for mRNA-1273 groups) and 19.3
595 days (arithmetic mean \pm 3.9 SD) after the boost (n=10 for BNT162b2 and n=10 for mRNA-1273
596 groups), were tested for IgG antibodies against SARS-CoV-2 full-length spike (**A** and **B**), BNT162b2
597 mRNA LNPs (**C** and **E**), and mRNA-1273 mRNA LNPs (**D** and **F**) by ELISA. Dotted line represents the
598 limit of detection (LOD) of the assay. Statistically significant differences between post-
599 prime/post-boost vs baseline antibody levels are shown. One-way ANOVA with Tukey's multiple
600 comparisons test. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.

601

602 **Figure 2. Antibodies against irrelevant lipid nanoparticles (LNPs) and polyethylene glycol (PEG)**
603 **in vaccinees' sera.** Sera from BNT162b2 (left column) or mRNA-1273 (right column) vaccinees
604 collected at baseline (n=10 for BNT162b2 and n=10 for mRNA-1273 groups), 18.9 days (arithmetic
605 mean \pm 2.4 SD) after the prime (n=10 for BNT162b2 and n=10 for mRNA-1273 groups) and 19.3
606 days (arithmetic mean \pm 3.9 SD) after the boost (n=10 for BNT162b2 and n=10 for mRNA-1273
607 groups), were tested for IgG antibodies against irrelevant LNPs (**A** and **B**), PEGylated BSA 20kDa
608 (**C** and **D**), 3.35kDa PEG (**E** and **F**) by ELISA. Dotted line represents the limit of detection (LOD) of
609 the assay. Statistically significant differences between post-prime/post-boost vs baseline
610 antibody levels are shown. One-way ANOVA with Tukey's multiple comparisons test. *, P < 0.05;
611 **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.

612

613 **Figure 3. Correlation of polyethylene glycol (PEG) reactive antibodies among different assays.**
614 Area under the curve (AUC) values obtained from the 20kDa PEGylated-BSA ELISA using mRNA-
615 1273 sera were analyzed for correlation with BNT162b2 formulation specific IgG (**A**), mRNA-1273
616 formulation specific IgG (**B**), irrelevant LNPs IgG (**C**), and PEG 3.35kDa specific IgG (**D**). Pearson
617 correlation was used. Statistically significant differences between post-prime/post-boost vs
618 baseline antibody levels are shown. One-way ANOVA with Tukey's multiple comparisons test. *,
619 P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.

620

621 **Figure 4. Levels of IgM and IgE antibodies against PEG and specificity of anti-PEG ELISA.** Sera
622 from BNT162b2 (left column) or mRNA-1273 (right column) vaccinees collected at baseline (n=10
623 for BNT162b2 and n=10 for mRNA-1273 groups), 18.9 days (arithmetic mean \pm 2.4 SD) after the
624 prime (n=10 for BNT162b2 and n=10 for mRNA-1273 groups) and 19.3 days (arithmetic mean
625 \pm 3.9 SD) after the boost (n=10 for BNT162b2 and n=10 for mRNA-1273 groups), were tested for
626 IgM (**A** and **B**) or IgE (**C** and **D**) antibodies against PEGylated BSA 20kDa or against bovine serum
627 albumin (BSA, **E** and **F**). Statistically significant differences between post-prime/post-boost vs
628 baseline antibody levels are shown. One-way ANOVA with Tukey's multiple comparisons test. *,
629 P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.

630

631 **Figure 5. Polyethylene glycol (PEG) antibodies in participants selected based on their vaccine**
632 **associated side effects including delayed onset injection site reactions and severe allergic**

633 **reaction.** Sera from BNT162b2 (**A**) or mRNA-1273 (**B**) vaccinees was collected at baseline (n=28
634 for **A and C**, and n=19 for **B and D**), 14.5 days (arithmetic mean \pm 4.8 SD) after the prime (n=23
635 for **A and C**, and n=17 for **B and D**) or 25.2 days (arithmetic mean \pm 11.6 SD) after the boost (n=26
636 for **A and C** and n=17 for **B and D**), and tested for IgG (**A and B**), IgM (**C and D**) or IgE (**E and F**)
637 antibodies against 20kDa PEGylated BSA by ELISA. Dotted line represents the limit of detection
638 (LoD) of the assay. Statistically significant differences between post-prime/post-boost vs baseline
639 antibody levels are shown. One-way ANOVA with Tukey's multiple comparisons test. *, P < 0.05;
640 **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.

641
642 **Supplementary Figure 1. Correlation of polyethylene glycol (PEG) reactive antibodies among**
643 **different assays (by vaccination time point).** Area under the curve (AUC) values obtained from
644 the 20kDa PEGylated-BSA ELISA using mRNA-1273 sera were analyzed for correlation with
645 BNT162b2 formulation specific IgG, mRNA-1273 formulation specific IgG, irrelevant LNPs IgG, and
646 3.35KDa PEG specific IgG, at baseline (left column), after the first vaccine dose administration
647 (central column) or after the boost (right column). Pearson correlation was used.

648
649 **Supplementary Figure 2. Controls used for measurement of IgE antibodies and for BSA ELISAs.**
650 The positive control used for measurement of antigen-specific IgE is shown in **A**. The positive
651 control used for measurement of BSA specific IgG is shown in **B**.

Figure 1









Figure 2











Figure 3


A



B



C



D





Figure 4

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).


A

**BNT162b2 vaccinees' sera vs
20kDa PEGylated BSA**




B

**mRNA-1273 vaccinees' sera vs
20kDa PEGylated BSA**




C

**BNT162b2 vaccinees' sera vs
20kDa PEGylated BSA**




D

**mRNA-1273 vaccinees' sera vs
20kDa PEGylated BSA**



E

**BNT162b2 vaccinees' sera vs
bovine serum albumin (BSA)**



F

**mRNA-1273 vaccinees' sera vs
bovine serum albumin (BSA)**




Figure 5

